

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Brunner, Hans R.

Appl. No.: 10/612,338

Filed: July 3, 2003

For: **Compositions and Methods Involving the
Combination of a Thromboxane A2 Receptor
Antagonist and an Inhibitor of Cyclooxygenase-2**



Art Unit: 1614

Examiner: S. Gembeh

Atty. Dkt.: 7571/80526

Response to Restriction Requirement

Commissioner of Patents
U.S. Patent and Trademark Office
Customer Service Window, **MS Amendment**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

In response to the Office Action dated September 12, 2006, in which the Examiner imposed a restriction requirement on the claims in the above-captioned application, Applicant hereby elects the claims of restriction Group I. This includes claims 1-17, directed to pharmaceutical compositions containing a COX-2 inhibitor and a thromboxane A2 receptor antagonist. As a species, Applicant elects ifetroban as the thromboxane A2 receptor antagonist and celecoxib as the COX-2 inhibitor.

This election is made without traverse.

Applicant does not believe that any fees, other than the Extension of Time fee already provided for herewith, are required for the filing of the present document. Nevertheless, any additional fees that may be needed may be charged to our Deposit Account No. 06-1135 under Order No. 7571/80526.

If, in the opinion of the Examiner, a phone call would help to expedite the prosecution of this application, the Examiner is invited to call Applicant's undersigned attorney at (202) 419-7013.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By: 

Michael A. Sanzo
Reg. No. 36,912
Attorney for Applicant

Date: October 12, 2006
One Lafayette Centre
1120 20th St. NW, Suite 750S
Washington, DC 20036
(202) 419-7013